Celecoxib reduces inflammation and angiogenesis in mice with adenomyosis

Area of Science:

• Reproductive biology
• Pharmacology

Background:

• Adenomyosis is a gynecological condition characterized by endometrial tissue within the myometrium.
• The precise mechanisms underlying adenomyosis pathogenesis are not fully understood.
• Cyclooxygenase-2 (COX-2) is implicated in inflammatory and proliferative processes relevant to adenomyosis.

Purpose of the Study:

• To investigate the therapeutic potential of a COX-2 selective inhibitor, celecoxib, in a mouse model of adenomyosis.
• To elucidate the molecular mechanisms by which celecoxib affects adenomyosis, focusing on key signaling molecules.

Main Methods:

• Establishment of a mouse model of adenomyosis.
• Treatment of adenomyosis model mice with celecoxib.
• Histological analysis (Hematoxylin-eosin staining) to assess endometrial infiltration depth.
• Gene and protein expression analysis using RT-PCR and Western blot for COX-2, VEGF, NGF, and CRH.

Main Results:

• Celecoxib treatment significantly reduced the depth of endometrial infiltration in the mouse adenomyosis model.
• Celecoxib significantly downregulated the expression of COX-2 and Vascular Endothelial Growth Factor (VEGF).
• No significant changes were observed in the expression of Nerve Growth Factor (NGF) or Corticotropin-Releasing Hormone (CRH) following celecoxib treatment.

Conclusions:

• COX-2 plays a significant role in the pathogenesis of adenomyosis.
• Celecoxib demonstrates therapeutic potential for adenomyosis by targeting COX-2.
• COX-2 inhibition represents a promising molecular target for future adenomyosis treatments.